|
Malignant neoplasm of breast
|
0.600 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes.
|
10086345 |
1999 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have recently identified a novel gene, TACC1 (transforming acidic coiled coil-containing gene 1), which is located close to FGFR1 within a region amplified in breast cancer on human chromosome 8p11.
|
10366448 |
1999 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study has identified new candidate oncogenes within the 8p11-p12 region, supporting the hypothesis that genes other than FGFR1 may contribute to oncogenesis in breast cancers with proximal 8p amplification.
|
14729606 |
2004 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The results revealed that the 8p11-p12 amplicon has a highly complex structure and that FGFR1 is not in the common core-amplified domain in 3 breast cancer cell lines with the amplicon.
|
15527903 |
2004 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To demonstrate the reliability of the probes generated with this protocol, four strategies were employed: (i) probes mapping to cyclin D1 (CCND1) were generated and their performance was compared with that of a commercially available probe for the same gene in a series of 10 FFPETS of breast cancer samples of which five harboured CCND1 amplification; (ii) probes targeting cyclin-dependent kinase 4 were used to validate an amplification identified by microarray-based comparative genomic hybridization (aCGH) in a pleomorphic adenoma; (iii) probes targeting fibroblast growth factor receptor 1 and CCND1 were used to validate amplifications mapping to these regions, as defined by aCGH, in an invasive lobular breast carcinoma with FISH and CISH; and (iv) gene-specific probes for ETV6 and NTRK3 were used to demonstrate the presence of t(12;15)(p12;q25) translocation in a case of breast secretory carcinoma with dual colour FISH.
|
16446704 |
2006 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recent studies have demonstrated that specific FGFR1 amplification correlates with gene expression and that FGFR1 activity is required for the survival of a FGFR1 amplified breast cancer cell line.
|
17397528 |
2007 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this review, we provide in this review a critical assessment of CISH and FISH and the impact of the analysis of amplification of specific oncogenes (eg, HER2, EGFR, MYC, CCND1, and FGFR1) and deletion of tumor suppressor genes (eg, BRCA1 and BRCA2) on our understanding of breast cancer.
|
17640550 |
2007 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have linked FGFR1 expression and single nucleotide polymorphisms in FGFR2 to breast cancer.
|
19601767 |
2009 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The goal of this study was to test the correlation between FGFR-1 amplification and expression and sensitivity to brivanib, an FGFR-1 small molecule inhibitor, in breast cancer cell lines in vitro.
|
20024612 |
2010 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
CTD_human |
Our data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance.
|
20179196 |
2010 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest that amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance.
|
20179196 |
2010 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Expression microarray analysis did not show transcriptional enhancement of Wnt/beta-catenin target genes but instead showed a translational gene signature that also correlated with elevated FGFR1 and FGFR2 in human breast cancer data sets.
|
20501844 |
2010 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
CTD_human |
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
|
21936542 |
2011 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
We confirm the in vivo relevance of our findings, showing that FGFR1 localized to the nucleus specifically in invading cells in both clinical material and a three-dimensional model of breast cancer.
|
22665522 |
2012 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although amplification of HER2, C-MYC, CCND1 and FGFR1 has been reported in breast cancers, their role in the progression of in situ to invasive breast carcinoma is unclear.
|
22863309 |
2012 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our aim was to clarify the roles of FGFR1-3 in breast cancer cell growth in vitro and in vivo.
|
23185502 |
2012 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Dovitinib also inhibits tumor growth in FGFR1-amplified breast cancer xenografts.
|
23658459 |
2013 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The results of our study strongly suggest that FGFR1-β is required for the pulmonary outgrowth of metastatic BC.
|
24618085 |
2014 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The mRNA and protein expression level of FGFR1 and other FGFRs were examined in several lines of breast cancer and osteosarcoma cells and corresponding normal cells using Taqman real-time quantitative PCR and Western blot analysis.
|
26201468 |
2015 |
|
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Consistent with animal studies, we found that in human BCa bone metastatic tissues, TGF-β type II receptor (TβRII) and p-Smad2 were expressed in osteoclasts and tumor cells, and were correlated with the expression of FGFR1.
|
26279296 |
2016 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
We evaluated FGFR1 expression in a large cohort of breast cancer by immunohistochemistry, correlated with the tumor clinic-pathologic features, biomarkers expression, and patient's survival.
|
26673008 |
2016 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Metastatic pmucBC is a distinct form of breast cancer that features a relatively high frequency of CRGA, including a significant enrichment of FGFR1 alterations and a high frequency of ERBB2 alterations when compared with non-metastatic pmucBC.
|
26762307 |
2016 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overall, the level of FGFR1 protein expression may be a biomarker of ER-positive/HER2-negative primary breast cancer with possible resistance to standard treatment, and may be a useful tool to identify more specific patients who would benefit from FGFR-1 targeted therapy.
|
26801869 |
2016 |
|
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Overall, the current studies demonstrate that FGFR1 works in concert with other EMT effector molecules to drive aberrant downstream signaling, and that these events can be effectively targeted using our novel therapeutics for the treatment of the most aggressive forms of breast cancer.
|
27371729 |
2016 |